114 related articles for article (PubMed ID: 28350209)
1. B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Xu T; Rothberg J; Lichenstein H
Autophagy; 2017 Jun; 13(6):1082-1083. PubMed ID: 28350209
[TBL] [Abstract][Full Text] [Related]
2. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Mandelkern T; Zheng M; Xu T; Rothberg J; Lichenstein H
Blood; 2017 Mar; 129(13):1768-1778. PubMed ID: 28104689
[TBL] [Abstract][Full Text] [Related]
3. Snx10 and PIKfyve are required for lysosome formation in osteoclasts.
Sultana F; Morse LR; Picotto G; Liu W; Jha PK; Odgren PR; Battaglino RA
J Cell Biochem; 2020 Apr; 121(4):2927-2937. PubMed ID: 31692073
[TBL] [Abstract][Full Text] [Related]
4. Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition.
Sano O; Kazetani K; Funata M; Fukuda Y; Matsui J; Iwata H
FEBS Lett; 2016 Jun; 590(11):1576-85. PubMed ID: 27135648
[TBL] [Abstract][Full Text] [Related]
5. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation.
Sbrissa D; Naisan G; Ikonomov OC; Shisheva A
PLoS One; 2018; 13(9):e0204532. PubMed ID: 30240452
[TBL] [Abstract][Full Text] [Related]
6. Lysosome enlargement during inhibition of the lipid kinase PIKfyve proceeds through lysosome coalescence.
Choy CH; Saffi G; Gray MA; Wallace C; Dayam RM; Ou ZA; Lenk G; Puertollano R; Watkins SC; Botelho RJ
J Cell Sci; 2018 May; 131(10):. PubMed ID: 29661845
[TBL] [Abstract][Full Text] [Related]
7. PIKfyve Deficiency in Myeloid Cells Impairs Lysosomal Homeostasis in Macrophages and Promotes Systemic Inflammation in Mice.
Min SH; Suzuki A; Weaver L; Guzman J; Chung Y; Jin H; Gonzalez F; Trasorras C; Zhao L; Spruce LA; Seeholzer SH; Behrens EM; Abrams CS
Mol Cell Biol; 2019 Nov; 39(21):. PubMed ID: 31427458
[TBL] [Abstract][Full Text] [Related]
8. Biogenesis of lysosome-related organelles complex-1 (BORC) regulates late endosomal/lysosomal size through PIKfyve-dependent phosphatidylinositol-3,5-bisphosphate.
Yordanov TE; Hipolito VEB; Liebscher G; Vogel GF; Stasyk T; Herrmann C; Geley S; Teis D; Botelho RJ; Hess MW; Huber LA
Traffic; 2019 Sep; 20(9):674-696. PubMed ID: 31314175
[TBL] [Abstract][Full Text] [Related]
9. PIKfyve inhibition interferes with phagosome and endosome maturation in macrophages.
Kim GH; Dayam RM; Prashar A; Terebiznik M; Botelho RJ
Traffic; 2014 Oct; 15(10):1143-63. PubMed ID: 25041080
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
11. Identification of PIKfyve kinase as a target in multiple myeloma.
de Campos CB; Zhu YX; Sepetov N; Romanov S; Bruins LA; Shi CX; Stein CK; Petit JL; Polito AN; Sharik ME; Meermeier EW; Ahmann GJ; Armenta IDL; Kruse J; Bergsagel PL; Chesi M; Meurice N; Braggio E; Stewart AK
Haematologica; 2020 Jun; 105(6):1641-1649. PubMed ID: 31582538
[TBL] [Abstract][Full Text] [Related]
12. PIKfyve activity regulates reformation of terminal storage lysosomes from endolysosomes.
Bissig C; Hurbain I; Raposo G; van Niel G
Traffic; 2017 Nov; 18(11):747-757. PubMed ID: 28857423
[TBL] [Abstract][Full Text] [Related]
13. PIKfyve inhibition increases exosome release and induces secretory autophagy.
Hessvik NP; Øverbye A; Brech A; Torgersen ML; Jakobsen IS; Sandvig K; Llorente A
Cell Mol Life Sci; 2016 Dec; 73(24):4717-4737. PubMed ID: 27438886
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of c-Rel DNA binding is critical for the anti-inflammatory effects of novel PIKfyve inhibitor.
Terajima M; Kaneko-Kobayashi Y; Nakamura N; Yuri M; Hiramoto M; Naitou M; Hattori K; Yokota H; Mizuhara H; Higashi Y
Eur J Pharmacol; 2016 Jun; 780():93-105. PubMed ID: 27001378
[TBL] [Abstract][Full Text] [Related]
15. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
[TBL] [Abstract][Full Text] [Related]
16. Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control.
Wible DJ; Parikh Z; Cho EJ; Chen MD; Jeter CR; Mukhopadhyay S; Dalby KN; Varadarajan S; Bratton SB
Cell Death Dis; 2024 Jan; 15(1):80. PubMed ID: 38253602
[TBL] [Abstract][Full Text] [Related]
17. PIKfyve inhibitor cytotoxicity requires AKT suppression and excessive cytoplasmic vacuolation.
Ikonomov OC; Altankov G; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2018 Oct; 356():151-158. PubMed ID: 30098992
[TBL] [Abstract][Full Text] [Related]
18. PIKfyve accelerates phagosome acidification through activation of TRPML1 while arrests aberrant vacuolation independent of the Ca2+ channel.
Isobe Y; Nigorikawa K; Tsurumi G; Takemasu S; Takasuga S; Kofuji S; Hazeki K
J Biochem; 2019 Jan; 165(1):75-84. PubMed ID: 30295876
[TBL] [Abstract][Full Text] [Related]
19. Giant Cellular Vacuoles Induced by Rare Earth Oxide Nanoparticles are Abnormally Enlarged Endo/Lysosomes and Promote mTOR-Dependent TFEB Nucleus Translocation.
Lin J; Shi SS; Zhang JQ; Zhang YJ; Zhang L; Liu Y; Jin PP; Wei PF; Shi RH; Zhou W; Wen LP
Small; 2016 Nov; 12(41):5759-5768. PubMed ID: 27593892
[TBL] [Abstract][Full Text] [Related]
20. Endosome maturation links PI3Kα signaling to lysosome repopulation during basal autophagy.
Rodgers SJ; Jones EI; Arumugam S; Hamila SA; Danne J; Gurung R; Eramo MJ; Nanayakkara R; Ramm G; McGrath MJ; Mitchell CA
EMBO J; 2022 Oct; 41(19):e110398. PubMed ID: 35968799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
